IDXX IDEXX Laboratories, Inc.
Nasdaq · Health Care · In Vitro & In Vivo Diagnostic Substances · Market cap $41.3B · $518.39 on 2026-10-02
Above StickerTier ADetailed (TTM)
Price moves
1 week-0%
1 month-3%
3 months-7%
6 months-9%
YTD-27%
1 year-18%
Off 52w high-33%
52w range$501–$770
Price history
Show year-end prices
| Year | Close |
|---|---|
| 2016 | $117.27 |
| 2017 | $156.38 |
| 2018 | $186.02 |
| 2019 | $261.13 |
| 2020 | $499.87 |
| 2021 | $658.46 |
| 2022 | $407.96 |
| 2023 | $555.05 |
| 2024 | $413.44 |
| 2025 | $676.53 |
| 2026-10-02 (latest) | $518.39 |
Ten Cap
$157
$157
Buy (MOS)
$213
$213
Payback Time
$248
$248
Sticker
$427
$427
Price
$518
$518
Valuation
| Buy (MOS) 50% of Sticker | $213.45 | -59% |
|---|---|---|
| Ten Cap 10× owner earnings | $157.30 | -70% |
| Payback Time 8-year FCF payback | $248.31 | -52% |
| Sticker Rule #1 intrinsic value | $426.90 | -18% |
| Windage growth g | 15.0% | |
| Future P/E (min 2g, 10y median) | 30.0× | |
| P/E · 10y median | 36.4× | 53.3× |
| EPS TTM 2026-06-30 | $14.23 | |
| FCF yield | 3.0% | |
| Revenue · net income last FY | $4.3B | $1.1B |
Big Five 12/15 tests ≥10%
| 10y | 5y | 1y | |
|---|---|---|---|
| ROIC | 51% | 50% | 55% |
| Sales growth | 10% | 10% | 10% |
| EPS growth | 20% | 14% | 23% |
| BVPS growth | – | 22% | 3% |
| OCF growth | 18% | 13% | 27% |
| Debt payoff (yrs of FCF) | 0.4 |
Events
-33% off 52w high; next report ~2026-11-03
Next report ≈ 2026-11-03 · SEC filings ·Yahoo Finance